Influx Healthtech (NSE:INFLUX) ROC %: 28.91% (As of Mar. 2026)


NSE:INFLUX Influx Healthtech Ltd NSE:INFLUX
21 GF Score
Price ₹301.10
! 4 Warning Signs
View Full Analysis

What is Influx Healthtech ROC %?

Influx Healthtech NSE:INFLUX +2.90% 21 ROC % is 28.91% as of Mar. 2026. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Influx Healthtech's annualized return on capital (ROC %) for the quarter that ended in Mar. 2026 was 28.91%.

As of today (2026-07-03), Influx Healthtech's WACC % is 13.04%. Influx Healthtech's ROC % is 34.28% (calculated using TTM income statement data). Influx Healthtech generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Influx Healthtech  (NSE:INFLUX) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Influx Healthtech's WACC % is 13.04%. Influx Healthtech's ROC % is 34.28% (calculated using TTM income statement data). Influx Healthtech generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Influx Healthtech ROC % Related Terms


Influx Healthtech ROC % Historical Data

* Premium members only.

The historical data trend for Influx Healthtech's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Influx Healthtech ROC % Chart

Influx Healthtech Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
ROC %
96.24 95.62 68.45 44.73 34.37

Influx Healthtech Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
ROC % Get a 7-Day Free Trial 0.00 50.95 40.97 41.84 28.91
NSE:INFLUX
21GF Score
Influx Healthtech Ltd NSE:INFLUX
ROC % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Influx Healthtech ROC % Calculation

Influx Healthtech's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2026 is calculated as:

ROC % (A: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2025 ) + Invested Capital (A: Mar. 2026 ))/ count )
=260.798 * ( 1 - 24.57% )/( (373.605 + 771.151)/ 2 )
=196.7199314/572.378
=34.37 %

where

Invested Capital(A: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=702.991 - 310.28 - ( 19.106 - max(0, 339.238 - 490.198+19.106))
=373.605

Invested Capital(A: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1237.03 - 191.226 - ( 274.653 - max(0, 227.116 - 814.628+274.653))
=771.151

Influx Healthtech's annualized Return on Capital (ROC %) for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=262.022 * ( 1 - 25.65% )/( (576.766 + 771.151)/ 2 )
=194.813357/673.9585
=28.91 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1135.402 - 193.018 - ( 365.618 - max(0, 232.918 - 825.585+365.618))
=576.766

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1237.03 - 191.226 - ( 274.653 - max(0, 227.116 - 814.628+274.653))
=771.151

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of 28.91% mean?
Influx Healthtech (NSE:INFLUX) has a ROC % of 28.91% as of Mar. 2026. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Influx Healthtech and its competitors.
Is Influx Healthtech's ROC % too high?
Influx Healthtech's current ROC % is 28.91%. The Drug Manufacturers industry median ROC % is 4.50. Influx Healthtech's value of 28.91% is 543.2% above this industry median. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's ROC % compare to ZTS and UTHR?
Influx Healthtech's ROC % of 28.91% can be compared against companies in the Drug Manufacturers industry. The industry median ROC % is 4.50. Influx Healthtech's value of 28.91% is 543.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Drug Manufacturers company?
The median ROC % among Drug Manufacturers companies is 4.50, based on 984 companies in the industry. Companies in the top quartile (top 25%) have a ROC % significantly above this median, while those in the bottom quartile fall well below. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current ROC % of 28.91% is 543.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median ROC % is 4.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current ROC % is 28.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current ROC % of 28.91%. The current ROC % is 28.91% and 543.2% above the Drug Manufacturers industry median of 4.50. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current ROC % is 28.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Influx Healthtech Business Description

Address Plot No. 856, 109, Ghanshyam Enclave Premises Co-op Society, Behind Laljipada Police Chowky, Kandivali West, Mumbai, MH, IND, 400067
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score

Get the complete analysis for NSE:INFLUX

ROC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹301.10
Price